Genzyme First Circuit Decision

by BakerHostetler

First Circuit Sides with Pharmaceutical Manufacturer in Dismissing Shareholder Class Action

In a huge victory for Massachusetts-based biologics manufacturer Genzyme Corporation, the First Circuit Court of Appeals on June 5, 2014 affirmed the District Court’s dismissal of a multi-million dollar shareholder class action stemming from allegedly misleading statements regarding the approval prospects for one of its best-selling drugs. Deka Int’l S.A. Luxembourg v. Genzyme Corp. (In re Genzyme Corp. Secs. Lit.), — F.3d —, 2014 WL 2535076 (1st Cir. June 5, 2014).  

The Court found that the allegations in the complaint failed to satisfy the “exacting standards” of the Private Securities Litigation Reform Act (“PSLRA”), which requires securities fraud complaints to contain allegations sufficient to create a “strong inference” of fraudulent intent. The Court held that the plaintiffs’ allegations lent themselves to a number of equally—if not more—compelling inferences that Genzyme executives acted innocently.

“Ill Organized and Convoluted” Complaint

The lawsuit stemmed from a plunge in Genzyme stock, which followed various disclosures throughout 2008 and 2009 regarding the fate of one of Genzyme’s FDA approval applications. Genzyme manufactures and markets drugs known as “biologics,” or drugs derived from biological sources rather than through chemical processes.  In April 2006, the FDA granted Genzyme’s “biologics license application” (“BLA”), and approved the manufacture of “Myozene,” a biologic used in the treatment of a rare metabolic disorder called Pompe disease. The approval permitted Genzyme to manufacture Myozene only on a small scale—using 160-liter “bioreactors.” However, after realizing Genzyme needed to ramp up output to meet rising demand, the company in 2007 filed a “supplemental” BLA seeking FDA approval to manufacture “Lumizyme,” or Myozene created in larger, 2,000-liter bioreactors.

According to the plaintiffs, Genzyme executives repeatedly misled investors about the fate of the Lumizyme supplemental BLA, concealing key red flags about the drug’s approval prospects and in the process artificially inflating Genzyme stock. They charged the defendants with violations of Sections 10(b) and 20(a) of the Securities Exchange Act.

The Court, however, said the complaint was an “ill organized and convoluted collection of 364 paragraphs” that failed to “muster sufficient strength to meet the formidable pleading standard set by Congress for securities fraud claims under Section 10(b).”

“Forward-Looking Projections” Not Actionable Under Section 10(b)

First, plaintiffs alleged the defendants failed to disclose a report from an October 2008 FDA inspection for its Allston, Massachusetts facility that “observed” several potential deviations from biologics manufacturing standards. According to the plaintiffs, Genyzme intentionally failed to mention the FDA’s report during an October 22, 2008 conference call, despite being aware of its importance to investors. In fact, Genzyme failed to disclose the FDA’s report until March 2, 2009, after it received a “Formal Warning Letter” from the FDA reiterating a number of issues from its October 2008 report, along with a “Complete Response Letter” stating Lumizyme approval was being withheld pending those issues’ resolution.

The Court held that the allegations—rather than supporting an inference of fraudulent intent—supported an alternative, equally plausible theory: that the defendants ultimately disclosed the FDA’s inspection report once its relevance “became apparent” to Genzyme.  The Court noted that Section 10(b) only imposes an affirmative duty to disclose information that is necessary to render earlier-disclosed information not misleading. Here, Genzyme had no reason to suspect it had previously misled investors about Lumizyme’s approval prospects until it received the February Warning Letter and the first Complete Response Letter, which “crystalized the relevance” of the FDA’s October 2008 report. This, along with the merely “observational” nature of the FDA’s October 2008 report, meant that Genzyme had no cause to believe that Lumizyme’s approval prospects were anything but solid.

Second, the plaintiffs alleged that the defendants fraudulently failed to disclose “bioreactor failure events” at two of its facilities, which purportedly jeopardized Lumizyme’s approval prospects. But the Court said the failures “bore no relation” to Lumizyme’s approval.  Further, Genzyme launched an internal investigation into the failures and disclosed its findings as soon as it ascertained the failures’ cause. The Court, admonishing that “a corporation cannot be expected to inform the market of any and all developments that might possibly affect stock value,” held that it was proper for Genzyme to open an inquiry and “wait for a complete picture to become apparent” before making any formal announcements.

Third, the plaintiffs asserted generally that the defendants deceived the market by falsely assuring investors that Lumizyme’s BLA would be approved.  For example, a Genzyme Vice President had told investors the likelihood of approval “seemed” to be “taking a more solid shape,” and Genzyme’s CEO stated Genzyme was “working very hard with the FDA to get everything done.” But the Court held that although the defendants used “rather rosy language to express optimism,” this language was “far from categorical” and made clear that approval “would be months away.” Genzyme’s communications “were accompanied, and supplemented, by full and prompt disclosure of all relevant communications from the FDA,... as well as revised earnings projections.” Accordingly, these were “mere forward-looking projections that [were] not actionable Section 10(b) transgressions.”

The Final Blow

The Court delivered the final blow to plaintiffs in denying their motion for leave to amend the complaint. Plaintiffs wanted to add new facts that allegedly strengthened their case as to the defendants’ fraudulent intent. Most of this information, however, was concededly available before the District Court’s decision—which occurred two years after the complaint was filed.  In other words, the plaintiffs had two years to present their new facts but failed to seize on that opportunity.

The Court did express “discomfort” with the District Court’s decision to dismiss the complaint without prejudice. It cautioned that the PSRLA did not alter the “liberal amendment policy” of the Federal Rules of Civil Procedure. Nevertheless, it was “within the bounds of the district court’s discretion” to do so, and the Court was not at liberty to alter that decision. This, of course, being no consolation for the plaintiffs, whose chances for recovery have been snuffed out completely.


DISCLAIMER: Because of the generality of this update, the information provided herein may not be applicable in all situations and should not be acted upon without specific legal advice based on particular situations.

© BakerHostetler | Attorney Advertising

Written by:


BakerHostetler on:

Readers' Choice 2017
Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up using*

Already signed up? Log in here

*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
Privacy Policy (Updated: October 8, 2015):

JD Supra provides users with access to its legal industry publishing services (the "Service") through its website (the "Website") as well as through other sources. Our policies with regard to data collection and use of personal information of users of the Service, regardless of the manner in which users access the Service, and visitors to the Website are set forth in this statement ("Policy"). By using the Service, you signify your acceptance of this Policy.

Information Collection and Use by JD Supra

JD Supra collects users' names, companies, titles, e-mail address and industry. JD Supra also tracks the pages that users visit, logs IP addresses and aggregates non-personally identifiable user data and browser type. This data is gathered using cookies and other technologies.

The information and data collected is used to authenticate users and to send notifications relating to the Service, including email alerts to which users have subscribed; to manage the Service and Website, to improve the Service and to customize the user's experience. This information is also provided to the authors of the content to give them insight into their readership and help them to improve their content, so that it is most useful for our users.

JD Supra does not sell, rent or otherwise provide your details to third parties, other than to the authors of the content on JD Supra.

If you prefer not to enable cookies, you may change your browser settings to disable cookies; however, please note that rejecting cookies while visiting the Website may result in certain parts of the Website not operating correctly or as efficiently as if cookies were allowed.

Email Choice/Opt-out

Users who opt in to receive emails may choose to no longer receive e-mail updates and newsletters by selecting the "opt-out of future email" option in the email they receive from JD Supra or in their JD Supra account management screen.


JD Supra takes reasonable precautions to insure that user information is kept private. We restrict access to user information to those individuals who reasonably need access to perform their job functions, such as our third party email service, customer service personnel and technical staff. However, please note that no method of transmitting or storing data is completely secure and we cannot guarantee the security of user information. Unauthorized entry or use, hardware or software failure, and other factors may compromise the security of user information at any time.

If you have reason to believe that your interaction with us is no longer secure, you must immediately notify us of the problem by contacting us at In the unlikely event that we believe that the security of your user information in our possession or control may have been compromised, we may seek to notify you of that development and, if so, will endeavor to do so as promptly as practicable under the circumstances.

Sharing and Disclosure of Information JD Supra Collects

Except as otherwise described in this privacy statement, JD Supra will not disclose personal information to any third party unless we believe that disclosure is necessary to: (1) comply with applicable laws; (2) respond to governmental inquiries or requests; (3) comply with valid legal process; (4) protect the rights, privacy, safety or property of JD Supra, users of the Service, Website visitors or the public; (5) permit us to pursue available remedies or limit the damages that we may sustain; and (6) enforce our Terms & Conditions of Use.

In the event there is a change in the corporate structure of JD Supra such as, but not limited to, merger, consolidation, sale, liquidation or transfer of substantial assets, JD Supra may, in its sole discretion, transfer, sell or assign information collected on and through the Service to one or more affiliated or unaffiliated third parties.

Links to Other Websites

This Website and the Service may contain links to other websites. The operator of such other websites may collect information about you, including through cookies or other technologies. If you are using the Service through the Website and link to another site, you will leave the Website and this Policy will not apply to your use of and activity on those other sites. We encourage you to read the legal notices posted on those sites, including their privacy policies. We shall have no responsibility or liability for your visitation to, and the data collection and use practices of, such other sites. This Policy applies solely to the information collected in connection with your use of this Website and does not apply to any practices conducted offline or in connection with any other websites.

Changes in Our Privacy Policy

We reserve the right to change this Policy at any time. Please refer to the date at the top of this page to determine when this Policy was last revised. Any changes to our privacy policy will become effective upon posting of the revised policy on the Website. By continuing to use the Service or Website following such changes, you will be deemed to have agreed to such changes. If you do not agree with the terms of this Policy, as it may be amended from time to time, in whole or part, please do not continue using the Service or the Website.

Contacting JD Supra

If you have any questions about this privacy statement, the practices of this site, your dealings with this Web site, or if you would like to change any of the information you have provided to us, please contact us at:

- hide
*With LinkedIn, you don't need to create a separate login to manage your free JD Supra account, and we can make suggestions based on your needs and interests. We will not post anything on LinkedIn in your name. Or, sign up using your email address.